糖尿病領域

• Clinical significance of imeglimin in older patients with type 2 diabetes: Analysis of a national database and a long-term case suggesting the potential for sarcopenia prevention.

  T. Fujisawa et al. Frontiers in Clinical Diabetes & Healthcare. 2025; 6: 1694522

• Bioequivalence assessment of imeglimin hydrochloride tablet, a novel glimin-class antidiabetic agent.

  Rezk Mamdouh R et al. Naunyn Schmiedebergs Arch Pharmacol. 2025 Nov 26. doi: 10.1007/s00210-025-04780-x. Online ahead of print.

• Comparison of the effect on treatment satisfaction of switching from multiple insulin injection therapy to additional administration of imeglimin in subjects with type 2 diabetes(MEGMI-TS): study protocol for a multicenter, prospective, randomized, open-label, parallel-group comparison trial.

  H. kitsunai et al. Trials. 2025;27(1):13

• Imeglimin in Patients with an Estimated Glomerular Filtration Rate Less than 45 mL/min per 1.73 m2: A Case Series

  S.Fukunaga　et al. JMA journal. 2025: 8: 4

• Comparative Efficacy and Safety of Imeglimin versus Metformin in Indian Adults with Type 2 Diabetes Mellitus: A 12-week Prospective Observational Comparative Study.

  Maurya, S.K. et al. International Journal of Life Sciences Biotechnology and Pharma Research. 2025: 14: 7: 1730-1735

• Imeglimin systematic review: a novel therapeutic approach for type 2 diabetes?unveiling benefits on β-cell function, insulin sensitivity, and potential long-term glycaemic control (HbA1c)

  Shireen, S. Murshidha et al. European Journal of Clinical Pharmacology. 2025: 45676

• Effect of imeglimin on metabolic dysfunction-associated steatotic liver disease in individuals with type 2 diabetes.

  Gyoutoku, N. et al. PLOS ONE. 2025: 20: 45940

• Potential Effect of Imeglimin on Mitochondrial Function in Subsynovial Connective Tissue of Idiopathic Carpal Tunnel SyndromeY.

  Ehara et al. Journal of Orthopaedic Research. 2025

• Imeglimin-based therapies improve glycemic control and reduce mitochondrial stress in type 2 diabetes: a prospective cohort study.

  Satheesan, Abhishek et al. Frontiers in Endocrinology. 2025: 16

• Imeglimin may affect hemoglobin A1c accuracy via prolongation of erythrocyte lifespan in patients with type 2 diabetes mellitus: insights from the INFINITY clinical trial

  T.Osonoi et al. Front Endocrinol (Lausanne). 2025 Oct 24:16:1699591.

• Effect of Imeglimin on mitochondrial function in patients with type 2 diabetes mellitus: a prospective cohort study

  Abhishek Satheesan et al. Front Endocrinol (Lausanne). 2025 Aug 1:16:1585834.

• Comparative effects of Imeglimin and empagliflozin on the redox-inflammation-organ stress axis in type 2 diabetes: a randomized controlled trial

  T.Otoda.et al. Discover Endocrinology and Metabolism. 2025; 1(4)

• Long-term safety and efficacy of imeglimin in Japanese individuals with type 2 diabetes and chronic kidney disease: A 52-week postmarketing clinical study (TWINKLE)

  T.Babazono et al. J Diabetes Investig. 2025 Aug 4. doi: 10.1111/jdi.70135. Online ahead of print.

• Safety and Efficacy of Imeglimin in Type 2 Diabetes Individuals with Metformin Intolerance: A Case-Control Study

  Agrawal et al.:Intractable & Rare Diseases Research 2025

• Efficacy and safety of imeglimin add-on to DPP-4 inhibitor therapy in Japanese patients with type 2 diabetes mellitus: An interim analysis of the randomised, double-blind FAMILIAR trial

  K. Kaku et al. Diabetes Obes Metab. 2025 Jun;27(6):3212-3222.

• Evaluation of Efficacy, Safety, and Tolerability of Imeglimin Hydrochloride SR Tablets 1000 mg in Participants with Inadequately Controlled Type 2 Diabetes Mellitus: A Phase III, Randomized, Double-Blind, Active-Controlled, Parallel Group, Multicenter Clinical Study from India

  Kumthekar, Prashan et al. Journal of Diabetology. 2025 16(2)182-189

• Verification of the Short-Term Impact of Imeglimin on Liver Fibrosis Markers Stratified by Liver Fibrosis Risk in Patients With Type 2 Diabetes

  T. Tanaka et al. Cureus. 2025

• Benefits and disadvantages of combination therapy with imeglimin and metformin in patients with type 2 diabetes.

  H. Ito et al. Expert Opin Pharmacother. 2025 Apr;26(6):773-781.

• Imeglimin and DPP-4 inhibitors: A promising therapeutic strategy for type 2 diabetes individuals with reduced insulin secretion

  Y. Hamamoto et al. Diabetes Obes Metab. 2025 Jul;27(7):4034-4036.

• Beneficial Role of Imeglimin as Add-on Drug with other Oral Hypoglycaemic Agents for Patients with Type 2 Diabetes: A Single centre Prospective Interventional Study.

  Parveen N et al. Journal of Clinical and Diagnostic Research　2025.19(2)

• Comparing the safety and effectiveness of imeglimin and vildagliptin as add-on therapies in type 2 diabetes patients: A record-based study

  Shambo Samrat Samajdar et al. International Journal of Diabetes in Developing Countries. 2025

• Efficacy of imeglimin in patients with type 2 diabetes mellitus complicated by metabolic dysfunction-associated steatotic liver disease: A multicentre study.

  K.Fukunaga et al. Diabetes Obes Metab. 2025 Mar;27(3):1498-1506.

• Efficacy of imeglimin treatment versus metformin dose escalation on glycemic control in subjects with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor plus low-dose metformin: A multicenter, prospective, randomized, open-label, parallel-group comparison study (MEGMI study).

  A.Takahashi et al. Diabetes Obes Metab. 2025 Mar;27(3):1466-1476.

• Differential effects of imeglimin and metformin on insulin and incretin secretion-An exploratory randomized controlled trial

  R.Usui et al. Diabetes Obes Metab. 2025 Feb;27(2):856-865

• A Multicenter, Retrospective Study to Evaluate the Effectiveness and Safety of Imeglimin in Patients with Type 2 Diabetes Mellitus in a Real-World Clinical Setting (INDI-TIMES Study).

  Shehla Shaikh et al. Diabetes Ther. 2025 Feb 19. doi: 10.1007/s13300-025-01693-z. Online ahead of print.

• Safety and Efficacy of Imeglimin for Type 2 Diabetes Mellitus in Patients With Heart Failure

  T.Nishikawa et al. In Vivo. 2025 Jan-Feb;39(1):375-380

• Effect of Imeglimin, a Novel Anti-Diabetic Agent, on Insulin Secretion and Glycemic Variability in Type 2 Diabetes Treated with DPP-4 Inhibitor: A 16-Week, Open Label, Pilot Study

  A.Itsukaichi et al. Diabetes Metab Syndr Obes. 2025 Jan 9:18:101-111. doi: 10.2147/DMSO.S495930. eCollection 2025.

• Effects of imeglimin on mitochondrial functions and ischemic brain damage in young and aging rats

  Paskeviciene, Evelina et al. Journal of Pharmacological Sciences. 2025

• Imeglimin attenuates liver fibrosis by inhibiting vesicular ATP release from hepatic stellate cells.

  S.Nomura et al. FEBS Letters. 2025

• Imeglimin alleviates high-glucose-induced bioenergetic and oxidative stress thereby enhancing intercellular adhesion in H9c2 cardiomyoblasts　

  H.Ohguro et al. International Journal of Molecular Sciences. 2025: 26: 18: 8913

• IN SILICO CHARACTERIZATION OF IMEGLIMIN’S INTERACTION WITH INFLAMMATORY AND MITOCHONDRIAL TARGETS USING MOLECULAR DOCKING AND MOLECULAR DYNAMICS

  YAZHINI P M et al. Asian Journal of Pharmaceutical and Clinical Research. 2025: 214-226

• Imeglimin enhances α-to-β reprograming mediated by PDX1 in β-cell ablated islets

  R.Fujishima.et al.Biochem Biophys Res Commun. 2025 Nov 1:790:152886.

• The distinct effects of metformin and imeglimin on high glucose-induced alterations in metabolic function and reactive oxygen species production in mouse Schwann cells are modulated by pemafibrate and/or fatty acid-binding proteins

  H.Ohguro et al. Front Cell Neurosci. 2025 Aug 22:19:1634262.

• Similarities and differences in the intestinal actions of metformin and imeglimin

  K.Sugawara et al. Diabetes Obes Metab. 2025 Sep 3. doi: 10.1111/dom.70075. Online ahead of print.

• Adenylosuccinate Mediates Imeglimin-Induced Proliferative and Antiapoptotic Effects in β-Cells

  R.Inoue et al. Diabetes. 2025 Sep 1;74(9):1589-1602

• Imeglimin suppresses glucagon secretion and induces a loss of α cell identity

  T.Tsuno et al. Cell Rep Med. 2025 Aug 19;6(8):102254.

• Combination of imeglimin and resistance exercise improves mitochondrial function and glucose metabolism in skeletal muscles

  H.Ishiguro et al. J Diabetes Complications. 2025 Oct;39(10):109145.

• Imeglimin improves hyperglycemia and hypoglycemia-induced cell death and mitochondrial dysfunction in immortalized adult mouse Schwann IMS32 cells.

  A.Kato et al. J Diabetes Investig. 2025 Sep;16(9):1586-1596.

• Imeglimin Inhibits Macrophage Foam Cell Formation and Atherosclerosis in Streptozotocin-Induced Diabetic ApoE-Deficient Mice

  Ji Yeon Lee et al. Cells. 2025 Mar 21;14(7):472.

• The Combination of PPARα Agonist GW7647 and Imeglimin Has Potent Effects on High-Glucose-Induced Cellular Biological Responses in Human Retinal Pigment Epithelium Cells

  N. Nishikiori et al. Bioengineering (Basel). 2025 Mar 8;12(3):265.

• High-Glucose-Induced Metabolic and Redox Alterations Are Distinctly Modulated by Various Antidiabetic Agents and Interventions Against FABP5/7, MITF and ANGPTL4 in Melanoma A375 Cells

  N. Nishikiori et al. Int J Mol Sci. 2025 Jan 24;26(3):1014.

• Imeglimin, unlike metformin, does not perturb differentiation of human induced pluripotent stem cells towards pancreatic beta-like cells and rather enhances gain in beta cell identity gene sets.

  T. Imada et al. J Diabetes Investig. 2025 Apr;16(4):584-597.

【その他】Review/Meta-analysis etc.

• Mitochondrial Dysfunction in Type 2 Diabetes Mellitus: Imeglimin as a Novel Therapeutic Approach.

  Kumar S et al. Asian Journal of Diabetology. 2025; 25(2): 6-20

• Predictors of glycemic control with imeglimin for type 2 diabetes: Results of machine learning analyses using clinical trial data

  K.Hagi et al.　Journal of Diabetes Investigation. 2025; 16(12): 2260-2284

• Evaluation and comparison of efficacy and safety of mitochondrial modulator (Imeglimin) and DPP-4 inhibitors in patients with type 2 diabetes mellitus: A Bayesian network meta-analysis.

  Chow, Junwei et al. Journal of Endocrinological Investigation. 2025: 45679

• Molecular mechanism for pancreatic beta-cell dysfunction and atherosclerosis and its therapeutic application: Importance of translational research bridging clinical practice and basic research.

  H.Kaneto et al. Journal of Diabetes Investigation. 2025

• Imeglimin as an effective therapeutic approach in management of type 2 diabetes mellitus: an umbrella review and systematic review, meta-regression and meta-analysis

  Qian Song et al. Diabetol Metab Syndr. 2025 Aug 27;17(1):357.

• Mechanisms and clinical perspectives on imeglimin for insulin resistance in obese patients.

  Hou T. et al. Eur J Pharmacol. 2025 Sep 15:1003:177937.

• Imeglimin in Type 2 Diabetes Mellitus: Expert Opinions and Consensus in Indian Context.

  Seshadri KG et al:Journal of the Association of Physicians of India 2025 73(6)e15-e22

• Gastrointestinal symptoms in patients receiving imeglimin in combination with metformin: A post-hoc analysis of imeglimin clinical trial data

  J.Ito et al. J Diabetes Investig. 2025 Apr;16(4):629-638.

• Efficacy and safety of imeglimin, a novel oral agent in the management of type 2 diabetes mellitus: a systematic review and meta-analysis.

  Jay Tewari et al. Naunyn Schmiedebergs Arch Pharmacol. 2025 Apr 30. doi: 10.1007/s00210-025-04198-5. Online ahead of print.

• Two Concerns and A Single Solution in Managing Type 2 Diabetes: A Narrative Review on Imeglimin

  Shambo Samrat Samajdar et al. J Assoc Physicians India. 2025 Jan;73(1):e14-e20.

• Glucose-Lowering Agents Developed in the Last Two Decades and Their Perioperative Implications.

  Goudra B. et al. Pharmaceuticals 2025, 18(1)

• IMEGLIMIN: A REVIEW

  Singh Aryan Pankaj et al.EPRA International Journal of Research and Development 2025;10(1)

• Glucokinase activators and imeglimin: New drugs against type 2 diabetes

  Mand, Sarah-Alivia et al. Lakartidningen 2025; 122

• 2型糖尿病患者におけるイメグリミンのアルブミン尿への影響
  内本 定彦ら　診療と新薬 2025:62:505-510
• イメグリミンの好適症例を探る －単施設での後方視的観察研究－

  岩本 正博ら　Therapeutic Research. 2025; 46(7): 469-474

• イメグリミン内服患者の肝切除術後に高度の乳酸アシドーシスを認めた一例

  日高 淳介ら　蘇生2025 44(1) 18-21

• 高齢2型糖尿病患者におけるイメグリミンの腎への影響

  内本 定彦ら　診療と新薬2025 62(4) 251-255

• 2型糖尿病患者におけるイメグリミン塩酸塩の有効性と安全性に関する検討　単施設後方視的研究

  村岡 愛ら.北海道農村医学会雑誌2025 57 77-85

• 高齢2型糖尿病患者におけるイメグリミン塩酸塩(ツイミーグ)の有効性と安全性の検討

  川口 祐司ら　新薬と臨床 2025 73巻12号1357-1368

• [糖尿病治療薬(ミトコンドリア機能改善薬)]イメグリミン(ツイミ-グR)

  吉田 昌史. 内科. 2025: 136: 3: 672-676

• 糖尿病薬の基本と使い分け 10.イメグリミン

  小田 智靖ら. レジデントノート. 2025: 27: 5: 913-919

• 【糖尿病薬物療法アップデート】イメグリミンの現在までの知見と今後の展望

  野本 博司　糖尿病. 2025; 68(5): 148-150

• 【新時代の臨床糖尿病学(下)-診断と治療の進歩-】薬物療法　各種血糖降下薬(インスリン以外)の作用,使用上の注意など　イメグリミン

  菅原 健二ら　日本臨床. 2025; 83(増刊3): 136-140

• mtROSを標的とした糖尿病合併症治療

  西川 武志　日本体質医学会雑誌 . 2025; 87(1): 1-5

• 【代謝領域　2型糖尿病治療のアップデート】イメグリミン

  廣田 勇士 日本内科学会雑誌2025 114(4) 643-647

• Imegliminの最新エビデンス

  大西 由希子　内科　2025年135巻3号　P448-452

• Potential Ketoacidosis Linked to Imeglimin and Metformin Co-administration in a Patient With Type 2 Diabetes.

  H.Yamagishi et al. Cureus. 2023 Jun 20;15(6):e40702.

• Comparative evaluation of clinical glycemic control markers treated with imeglimin and its effect on erythrocytes in patients with type 2 diabetes mellitus: study protocol of a single-arm, open-label, prospective, exploratory trial.

  T.Osonoi et al. Front Pharmacol. 2023 Jun 7;14:1205021.

• Safety and Efficacy of Imeglimin for Type 2 Diabetes in Patients Undergoing Dialysis.

  A.Mima In Vivo. 2023 May-Jun;37(3):1334-1338.

• A consensus statement from the Japan Diabetes Society: A proposed algorithm for pharmacotherapy in people with type 2 diabetes.

  R.Bouchi et al. J Diabetes Investig. 2023 Jan;14(1):151-164.

• Improving the Effects of Imeglimin on Endothelial Function: A Prospective, Single-Center, Observational Study.

  T.Uchida et al. Diabetes Ther. 2023 Mar;14(3):569-579.

• Pharmacokinetics and Safety of Imegliminin Japanese Patients With Impaired RenalFunction.

  A.Kitamura et al. The Journal of Clinical Pharmacology. 2023,63(7):807-816

• Imeglimin profoundly affects the circadian clock in mouse embryonic fibroblasts.

  K.Miura et al. J Pharmacol Sci. 2023 Dec;153(4):215-220.

• A sensitive direct chiral liquid chromatography tandem mass spectrometry method for the enantio-Selective analysis of imeglimin in formulation.

  S.Ramalingam et al. Journal of Applied Pharmaceutical Science July, 2023, Vol.13(07), 214-219

• Imeglimin prevents visceral hypersensitivity and colonic hyperpermeability in irritable bowel syndrome rat model.

  T.Nozu et al. J Pharmacol Sci. 2023 Sep;153(1):26-30.

• Discovery of imeglimin-inspired novel 1,3,5-triazine derivatives as antidiabetic agents in streptozotocin-induced diabetes in Wistar rats via inhibition of DPP-4.

  Akanksha Gupta et al. Future Med Chem 2023 May;15(10):829-852.

• Protective effects of imeglimin and metformin combination therapy on β-cells in db/db male mice.

  K.Nishiyama et al. Endocrinology. 2023 Jun 14;bqad095.

• Stimulatory effect of imeglimin on incretin secretion.

  Q.Yingyue et al. J Diabetes Investig. 2023 Jun;14(6):746-755.

• Effects of imeglimin on mitochondrial function, AMPK activity, and gene expression in hepatocytes.

  K.Hozumi et al. Sci Rep. 2023 Jan 13;13(1):746.

• Novel Approaches to the Management of Diabetes Mellitus in Patients with Coronary Artery Disease.

  E.Oikonomou et al. Curr Pharm Des. 2023;29(23):1844-1862.

• Mitochondrial Dysfunction and Imeglimin: A New Ray of Hope for the Treatment of Type-2 Diabetes Mellitus.

  J.Swain et al. Mini Rev Med Chem. 2023 Oct 10. Online ahead of print.

• Early Combination Therapies for the Preservation of Pancreatic β Cells in Type 2 Diabetes Mellitus.

  Nadia Rachdaoui, Endocrinology. 2023 Aug 28;164(10):bqad134.

• The role of Imeglimin in glycemic control, beta cell function and safety outcomes in patients with type 2 diabetes mellitus: A comprehensive meta-analysis.

  P.Vinayagam et al. Diabetes Epidemiology and Management 12 (2023) 100164

• Imeglimin: A Clinical Pharmacology Review.

  C.Chevalier et al. Clin Pharmacokinet. 2023 Oct;62(10):1393-1411.

• Efficacy, safety and tolerability of imeglimin in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.

  K.Hagi et al. J Diabetes Investig. 2023 Nov;14(11):1246-1261.

• Effect of patient characteristics on the efficacy and safety of imeglimin monotherapy in Japanese patients with type 2 diabetes mellitus: A post-hoc analysis of two randomized, placebo-controlled trials.

  K.Hagi et al. J Diabetes Investig. 2023 Sep;14(9):1101-1109.

• Glucose-Lowering Effects of Imeglimin and Its Possible Beneficial Effects on Diabetic Complications.

  H.Yanai et al. Biology (Basel). 2023 May 16;12(5):726.

• Mitochondrion: A bridge linking aging and degenerative diseases.

  Lanlan Zhang et al. Life Sci. 2023 Jun 1;322:121666.

• Anti-Diabetic Therapy and Heart Failure: Recent Advances in Clinical Evidence and Molecular Mechanism.

  Chih-Neng Hsu et al. Life (Basel). 2023 Apr 16;13(4):1024.

• Efficacy and safety of imeglimin in type 2 diabetes: A systematic review and meta-analysis of randomized placebo-controlled trials.

  A.Kumar Singh et al. Diabetes Metab Syndr. 2023 Feb;17(2):102710.

2022年

• Pharmacokinetics of Imeglimin in Caucasian and Japanese Healthy Subjects.

  P.Fouqueray et al. Clin Drug Investig. 2022 Sep;42(9):721-732.

• Add-on imeglimin versus metformin dose escalation regarding glycemic control in patients with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor plus low-dose metformin: study protocol for a multicenter, prospective, randomized, open-label, parallel-group comparison study (MEGMI study).

  H.Nomoto et al. BMJ Open Diabetes Res Care. 2022 Nov;10(6):e002988.

• Phase 2 trial with imeglimin in patients with Type 2 diabetes indicates effects on insulin secretion and sensitivity.

  P.Theurey et al. Endocrinol Diabetes Metab. 2022 Nov;5(6):e371.

• Efficacy and safety of imeglimin add-on to insulin monotherapy in Japanese patients with type 2 diabetes (TIMES 3): A randomized, double-blind, placebo-controlled phase 3 trial with a 36-week open-label extension period.

  C.Reihac et al. Diabetes Obes Metab. 2022 May;24(5):838-848.

• The Effects of Imeglimin on the Daily Glycemic Profile Evaluated by Intermittently Scanned Continuous Glucose Monitoring: Retrospective, Single-Center, Observational Study.

  T.Oda et al. Diabetes Ther. 2022 Sep;13(9):1635-1643.

• Imeglimin population pharmacokinetics and dose adjustment predictions for renal impairment in Japanese and Western patients with type 2 diabetes.

  Y.Tomita et al. Clin Transl Sci. 2022 Apr;15(4):1014-1026.

• Imeglimin Is Neuroprotective Against Ischemic Brain Injury in Rats-a Study Evaluating Neuroinflammation and Mitochondrial Functions.

  G.Zemgulyte et al. Mol Neurobiol. 2022 May;59(5):2977-2991.

• Imeglimin exerts favorable effects on pancreatic β-cells by improving morphology in mitochondria and increasing the number of insulin granules.

  J.Sanada et al. Scientific Reports. 2022 Aug 2;12(1):13220.

• Preservation effect of imeglimin on pancreatic β-cell mass: Noninvasive evaluation using 111In-exendin-4 SPECT/CT imaging and the perspective of mitochondrial involvements.

  M.Fauzi et al. Front Endocrinol (Lausanne). 2022 Sep 29;13:1010825.

• Reduced lactic acidosis risk with Imeglimin: Comparison with Metformin.

  P.Theurey et al. Physiol Rep. 2022 Mar;10(5):e15151.

• The Influence of Lifestyle and Treatment on Oxidative Stress and Inflammation in Diabetes.

  Magdalena Wronka et al. Int J Mol Sci. 2022 Dec 12;23(24):15743.

• Person-centered choice of anti-obesity pharmacotherapy.

  Sanjay Kalra et al. Journal of the Pakistan Medical Association. Vol.72, No.7, July2022

• Mitochondrial and metabolic dysfunction in ageing and age-related diseases.

  J.A Amorim et al. Nat Rev Endocrinol. 2022 Apr;18(4):243-258.

• Treatment of diabetes mellitus has borne much fruit in the prevention of cardiovascular disease.

  H.yagyu et al. J Diabetes Investig. 2022 Sep;13(9):1472-1488.

• New Horizons: Emerging Antidiabetic Medications.

  G.Mingrone et al. J Clin Endocrinol Metab. 2022 Nov 25;107(12):e4333-e4340.

• Ferroptosis in heart failure.

  X.Yang et al. J Mol Cell Cardiol. 2022 Dec;173:141-153.

• The Influence of Lifestyle and Treatment on Oxidative Stress and Inflammation in Diabetes.

  M.Wronka et al. Int J Mol Sci. 2022 Dec 12;23(24):15743.

• Imeglimin to the Rescue: Enhanced CHOP/GADD34/eIF2α Signaling Axis Promotes β-Cell Survival.

  S.Jo et al. Diabetes. 2022 Mar 1;71(3):376-378.

• Mitochondria-targeted drugs for diabetic kidney disease.

  A.Mima Heliyon. 2022 Feb 3;8(2):e08878.

2021年

• Efficacy and Safety of Imeglimin Monotherapy Versus Placebo in Japanese Patients With Type 2 Diabetes (TIMES 1): A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Phase 3 Trial.

  J.Dubourg et al. Diabetes Care. 2021 Apr;44(4):952-959.

• Efficacy and safety of imeglimin in Japanese patients with type 2 diabetes: A 24-week, randomized, double-blind, placebo-controlled, dose-ranging phase 2b trial.

  J.Dubourg et al. Diabetes Obes Metab. 2021 Mar;23(3):800-810.

• Pharmacokinetics of Imeglimin in Subjects with Moderate Hepatic Impairment.

  C.Chevalier et al. Clin Pharmacokinet. 2021 Apr;60(4):485-490.

• Imeglimin prevents visceral hypersensitivity and colonic hyperpermeability in irritable bowel syndrome rat model.

  N.Tsukasa et al. Biomed Pharmacother. 2021 Jul;139:111649.

• Imeglimin amplifies glucose-stimulated insulin release from diabetic islets via a distinct mechanism of action.

  S.Hallakou-Bozec et al. PLoS One. 2021 Feb 19;16(2):e0241651.

• Imeglimin ameliorates β-cell apoptosis by modulating the endoplasmic reticulum homeostasis pathway.

  Jinghe Li et al. Diabetes. 2022 Mar 1;71(3):424-439.

• A novel mechanism of imeglimin-mediated insulin secretion via the cADPR-TRP channel pathway.

  S.Funazaki et al. J Diabetes Investig. 2022 Jan;13(1):34-41.

• Imeglimin prevents heart failure with preserved ejection fraction by recovering the impaired unfolded protein response in mice subjected to cardiometabolic stress.

  H.Kitakata et al. Biochem Biophys Res Commun. 2021 Oct 1;572:185-190.

• The mechanism by which imeglimin inhibits gluconeogenesis in rat liver cells.

  G.Vial et al. Endocrinol Diabetes Metab. 2021 Feb 23;4(2):e00211.

• Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes.

  S.Hallakou-Bozec et al. Diabetes Obes Metab. 2021 Mar;23(3):664-673.

• Imeglimin: Current Development and Future Potential in Type 2 Diabetes.

  Chigoziri Konkwo et al. Drugs. 2021 Feb;81(2):185-190.

• Imeglimin: A New Promising and Effective Weapon in the Treatment of Type 2 Diabetes.

  J.Doupis et al. touchREV Endocrinol. 2021 Nov;17(2):88-91.

• Novel approaches to pharmacological management of type 2 diabetes in Japan.

  S.Kaneko Expert Opin Pharmacother. 2021 Nov;22(16):2235-2249.

2020年

• Long-term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes (TIMES 2): A 52-week, open-label, multicentre phase 3 trial.

  J.Dubourg et al. Diabetes Obes Metab. 2022 Apr;24(4):609-619.

• Absence of QTc prolongation in a thorough QT study with imeglimin, a first in class oral agent for type 2 diabetes mellitus.

  J.Dubourg et al. Eur J Clin Pharmacol. 2020 Oct;76(10):1393-1400.

• Lack of Drug–Drug Interaction Between Cimetidine, a Renal Transporter Inhibitor, and Imeglimin, a Novel Oral Antidiabetic Drug, in Healthy Volunteers.

  C.Chevalier et al. Eur J Drug Metab Pharmacokinet. 2020 Dec;45(6):725-733.

• Imeglimin Does Not Induce Clinically Relevant Pharmacokinetic Interactions When Combined with Either Metformin or Sitagliptin in Healthy Subjects.

  P.Fouqueray et al. Clin Pharmacokinet. 2020 Oct;59(10):1261-1271.

• In Vitro Investigation, Pharmacokinetics, and Disposition of　Imeglimin, a Novel Oral Antidiabetic Drug, in Preclinical Species and　Humans.

  C.Clémence et al. Drug Metab Dispos. 2020 Dec;48(12):1330-1346.

• Imeglimin preserves islet β-cell mass in Type 2 diabetic ZDF rats.

  S.Hallakou-Bozec et al. Endocrinol Diabetes Metab. 2020 Nov 7;4(2):e00193.

• Short-and long-term administration of imeglimin counters cardiorenal dysfunction in a rat model of metabolic syndrome.

  M.Lachaux et al. Endocrinol Diabetes Metab. 2020 Apr 16;3(3):e00128.

• Imeglimin, a novel, first in-class, blood glucose-lowering agent: a systematic review and meta-analysis of clinical evidence.

  T.SJ Crabtree et al. THE BRITISH JOURNAL OF DIABETES, 2020 JUNE; VOLUME 20 ISSUE 1

～2019年

• Imeglimin increases glucose-dependent insulin secretion and improves β-cell function in patients with type 2 diabetes.

  G.Pacini et al. Diabetes Obes Metab. 2015 Jun;17(6):541-545.

• The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Sitagliptin Monotherapy.

  P.Fouqueray et al. Diabetes Care. 2014 Jul;37(7):1924-30.

• The Efficacy and Safety of Imeglimin as Add-on Therapy in PatientsWith Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy.

  P.Fouqueray et al. Diabetes Care. 2013 Mar;36(3):565-8.

• Imeglimin, a novel glimin oral antidiabetic, exhibits a good efficacy and safety profile in type 2 diabetic patients.

  V.Pirags et al. Diabetes Obes Metab. 2012 Sep;14(9):852-8.

• Imeglimin lowers glucose primarily by amplifying glucose-stimulated insulin secretion in high-fat-fed rodents.

  R. J Perry et al. Am J Physiol Endocrinol Metab. 2016 Aug 1;311(2):E461-70.

• Imeglimin prevents human endothelial cell death by inhibiting mitochondrial permeability transition without inhibiting mitochondrial respiration.

  D.Detaille et al. Cell Death Discov. 2016 Jan 18;2:15072.

• Imeglimin Normalizes Glucose Tolerance and Insulin Sensitivity and Improves Mitochondrial Function in Liver of a High-Fat, High-Sucrose Diet Mice Model.

  G.Vial et al. Diabetes. 2015 Jun;64(6):2254-64.

• Imeglimin - A New Oral Anti-Diabetic that Targets the Three Key Defects of Type 2 Diabetes.

  P.Fouqueray et al. J Diabetes Metab 2011, 2:4

• Possibility of a New Therapeutic Strategy for Left Ventricular Dysfunction in Type 2 Diabetes.

  M.Sakamoto et al. J Clin Med Res. 2018 Nov;10(11):799-805.

2024年

• 2型糖尿病患者におけるイメグリミンのメトホルミン治療への追加または切替による有効性への影響
  遅野井 健ら　診療と新薬　61巻, 295-302, 2024　

• 【病態　治療　ケアの基本をギュッと凝縮!糖尿病看護はじめてナビ】(第5章)糖尿病薬物療法　血糖降下薬
  山下 みどり　糖尿病ケア+　春季増刊　122-136、2024

• 【薬の使い方がすぐわかる　泌尿器科処方ガイド】周術期　ハイリスク患者の管理　血糖降下薬服薬中の患者
  今井 恵理哉, 横塚 基　臨床泌尿器科　78巻4号, 283-288, 2024

• 2型糖尿病患者における実臨床下でのイメグリミンの長期使用成績
  遅野井 健ら　診療と新薬　61巻4号, 243-253, 2024

• 【10年間で登場した薬剤の市販後を総点検!病棟頻用薬の通信簿】(PART.2)承認後3年～7年未満(2018～2021)　イメグリミン
  加賀 英義, 綿田 裕孝　月刊薬事　66巻6号, 1084-1089, 2024

• 【新しい時代をむかえた糖尿病の診療】糖尿病治療薬　スルホニル尿素薬とイメグリミンから考えるインスリン分泌促進薬
  川浪大治　臨牀と研究　101巻２号

2023年

• 新しい糖尿病治療薬イメグリミンの短期使用成績　その効果と問題点

  田中剛史ら　Therapeutic Research　44巻10号, 765-771, 2023

• ミトコンドリア由来活性酸素と糖尿病合併症

  西川武志　糖尿病・内分泌代謝科　27巻1号, 117-124, 2023

• TRPM2とインスリン分泌

  吉田昌史　糖尿病・内分泌代謝科　27巻1号, 89-96, 2023

• 糖尿病治療薬とがんリスク

  川北恵美ら　医学のあゆみ　286巻10号, 769-776, 2023

• 2型糖尿病に対するイメグリミン塩酸塩の有効性の評価と好適患者の考察

  川口祐司ら　新薬と臨牀 72(9): 739-750, 2023.

• まずはこれだけ!内科外来で必要な薬剤 自信をもって処方ができる,自家薬籠中のリスト 6 糖尿病治療薬

  本間博之　シリーズGノート, 2023.

• プライマリケア医に必要な情報をまるっと整理 くすりの使い方便利帳 第6章 代謝系に作用する薬剤[糖尿病治療薬]imeglimin

  小田知靖　内科　131巻4号 P.816-820

• 【-自信がもてるようになる!-エビデンスに基づく「糖尿病診療」大全-新薬からトピックスまで】(I章)「薬物療法」の新スタンダード　メトホルミンとイメグリミン

  藤嶋伶ら 総合診療　33巻3号 P.274-275

• 【変わりゆく高齢者の循環器診療】高齢者糖尿病の特徴と治療

  荒木厚　心臓　55巻1号 P.19-26

• 【糖尿病とミトコンドリア-両者の多様な関係性と創薬の視点-】イメグリミンの臨床試験

  粟澤元晴ら　糖尿病プラクティス　39巻3号 P.264-269

• 【糖尿病とミトコンドリア-両者の多様な関係性と創薬の視点-】イメグリミンの作用機序

  飯田雅ら　糖尿病プラクティス　39巻3号 P.258-263

• 【心腎連関から新薬まで!心×腎疾患の薬物治療】心腎領域の新薬　イメグリミン　糖尿病

  松下真弥　薬事　64巻4号 P.763-767

• 膵作用と膵外作用の2 つの血糖降下作用をあわせもつ世界初の経口2 型糖尿病治療薬イメグリミン塩酸塩（ツイミーグ®錠）の薬理学的特性と臨床効果

  長嶺純　日薬理誌(Folia Pharmacol. Jpn.) , 2023, 158，P.1～10

• エビデンスに基づく「糖尿病診療」大全 新薬からトピックスまで I章「薬物療法」の新スタンダード 3)メトホルミンとイメグリミン

  藤嶋伶ら　総合診療, 33巻3号 P.274-275

• 作用機序から低血糖予防までサクッと解説 すぐに患者に話したくなるすべらない糖尿病治療薬のはなし 2 現場で役立つ・ためになる!糖尿病治療薬のすべらないはなし 7 イメグリミン

  坂倉圭一　糖尿病ケア＋, 2023, 20巻2号, P196-199

2022年

• 病態に合わせた処方の基本 6 新しい糖尿病薬の使い方は?～イメグリミンの特徴は?

  森下啓明ら　シリーズGノート, 2022, P.50-55

• 病態に合わせた処方の基本 4 肥満が気になる人の処方は?

  内田大学　シリーズGノート, 2022, P.37-42

• 病態に合わせた処方の基本 3 ガイドラインに基づいた2型糖尿病の処方は?

  能登洋　シリーズGノート, 2022, P.29-36

• 特殊な病態の治療 4 高齢者への糖尿病薬の処方は?

  荒木厚　シリーズGノート, 2022, P.134-140

• 糖尿病の療養指導Q&A「糖尿病治療ガイド2022‐2023」の改訂のポイント

  綿田裕孝　糖尿病プラクティス, 2022, 39巻6号 P.686-688

• 【糖尿病治療　次の一手を考える】広がった,糖尿病薬物療法の選択肢

  下野大　月刊糖尿病, 2022, 14巻5号 P.40-45

• ミトコンドリア由来活性酸素種によるインスリン分泌障害機構とイメグリミンによる介入効果

  堺弘治　糖尿病プラクティス, 2022, 39巻6号 P.700

• 心血管病の治療薬・予防薬の進歩:最新薬物治療のエッセンス 薬物療法のエッセンス:病態別・疾患別の使いかた 2型糖尿病の薬物治療

  安藤清香ら　診断と治療, 2022, 110巻10号 P.1281-1285

• 2型糖尿病患者における日常診療下でのイメグリミン塩酸塩の有効性および安全性プロファイルの特徴

  遅野井健ら　診療と新薬, 2022, 59巻10号, P.628-636

• 2型糖尿病患者におけるイメグリミンの赤血球に及ぼす影響

  遅野井健ら　診療と新薬, 2022, 59巻12号, P.745-752

• 糖尿病診療update II.糖尿病治療薬に関する最近の話題 新しい薬剤の話題 イメグリミンの作用機構と使い方

  加賀英義ら　日本臨牀, 2022, 80号 P.645-649

• 糖尿病とミトコンドリア―両者の多様な関係性と創薬の視点―2 イメグリミンの臨床試験

  粟澤元晴ら　糖尿病プラクティス, 2022, 39巻3号 P.264-269

• 糖尿病とミトコンドリア―両者の多様な関係性と創薬の視点―1 イメグリミンの作用機序

  飯田雅ら　糖尿病プラクティス, 2022, 39巻3号 P.258-263

• 新しい血糖コントロールの考え方と治療薬 1)新しい血糖コントロールを考えた内服治療

  辻野 大助ら　Bio Clinica, 2022, 37巻10号 P.884-889

• 幹細胞・膵島再生研究と展望

  都野貴寛ら　月刊糖尿病・内分泌代謝科, 2022, 54巻1号 P.74-83

• 最新の糖尿病診療と今後の展開 糖尿病治療薬Update その他の糖尿病治療薬

  飯田雅ら　内科, 2022, 129巻5号

• 新規糖尿病治療薬イメグリミン

  白川純　臨床栄養, 2022, 140巻 P.284-286

• 注目の新薬 ツイミーグ錠(イメグリミン塩酸塩錠)

  綿田裕孝ら　診断と治療, 2022, 110巻3号 P.377-381

• 2型糖尿病の病態生理を一例一例で理解し,治療手段を活用しよう

  河盛隆造　Clinic Magazine, 2022, 49巻1号 P.12-20

• クリニカルクエスチョンで学ぶ糖尿病治療薬 糖尿病治療の新しい潮流 カテゴリー別・糖尿病治療薬の特徴 ミトコンドリア機能改善薬

  遅野井健　Medicina, 2022, 59巻1号

2021年

• 高齢者糖尿病におけるエビデンス―利益とリスクを考慮した治療―5.新薬の話題:高齢者に対するイメグリミンなどへの期待

  加藤誠ら　Progress in Medicine, 2021, 41巻9号　P.859-863

• 内分泌代謝領域での新たな治療薬・治療法 イメグリミンの作用機序と血糖降下作用

  植木浩二郎　月刊糖尿病・内分泌代謝科, 2021, 53巻3号 P.270-273

• 最近の糖尿病治療薬の展望 ミトコンドリアを標的とした新しい作用機序の抗糖尿病薬イメグリミン

  植木浩二郎　カレントテラピー, 2021, 39巻5号 P.433-436

• Drug 薬剤 第1回 これからの2型糖尿病治療薬:imeglimin

  中村昭伸　糖尿病プラクティス, 2021, 38巻1号 P.84-86

• イメグリミンの作用機構とポジショニング

  植木浩二郎　医学のあゆみ, 2021, 276巻5号 P.537-540

• 慢性腎臓病 III.診断と治療(リスクファクターの治療を含む)診断と治療(新規治療薬への期待)SGLT2阻害薬とGLP‐1受容体作動薬

  黒岡直子ら　日本臨牀, 2021, 79号 P.1853-1859

• 目標を見据えた高齢者糖尿病管理～実態の理解から薬物療法まで～II.高齢者糖尿病の診療の実際 II‐3 高齢者糖尿病の薬物療法

  伊藤禄郎ら　月刊糖尿病, 2021, 13巻11号 p.29-39

• 経口血糖降下薬の温故知新 9 イメグリミン～ミトコンドリア機能を改善する経口糖尿病薬～

  野村政壽ら　月刊糖尿病, 2021, 13巻12号 P.61-67

• Pathogenesis & Diagnosis 病因と診断 第3回 糖尿病の病因と診断(3)

  堀川幸男　糖尿病プラクティス, 2021, 38号 P.689-692

2020年

• 糖尿病診療update V.特論 新規糖尿病治療薬の開発動向

  白川純ら　日本臨牀, 2020, 78巻7号 P.1242-1248

• NAFLD/NASH,肝がんの診断と治療―基礎研究から臨床応用へ―7.NAFLD/NASHの治療戦略 3)糖尿病合併症例の薬物治療選択肢

  金子景弘ら　Progress in Medicine, 2020, 40巻5号 P.503-507

• イメグリミン

  植木浩二郎　月刊糖尿病・内分泌代謝科, 2020, 50巻5号 P.383-386

• 糖尿病の合併症(腎・眼・心血管疾患)―新しい抗糖尿病薬で予後は変わるか 治療薬解説 イメグリミン

  藤田義人ら　カレントテラピー, 2020, 38巻4号 P.386-391

～2019年

• 新薬展望2019 第III部 治療における最近の新薬の位置付け〈薬効別〉～新薬の広場～糖尿病治療薬

  大場知穂ら　医薬ジャーナル, 2019, 55巻 P.370-377

• 糖尿病の療養指導Q&A イメグリミン

  細井雅之ら　プラクティス, 2018, 35巻4号 P.452-453

• インスリン分泌促進系薬 インスリン分泌促進薬の種類

  佐藤源記ら　糖尿病の最新治療, 2017, 9巻1号 P.14-19

• 糖尿病合併症―発症・進展の分子機序―ミトコンドリア由来活性酸素

  西川武志ら　日本臨牀, 2016, 74巻 P.67-72